- Therapeutic (alone or in combination) for cardiac arrhythmias
- Research tool to knock-down miR-448 and or upregulate SCN5A
- Cancer therapeutic (for cancers where miR-448 is relevant)
Arrhythmic cardiomyopathy can cause severe problems including cardiac arrest and death. Unfortunately, many of the therapeutics to treat arrhythmias can actually have pro-arrhythmic side effects. This technology is an antagomir targeting miR-448 (anti-miR-448), a microRNA linked to the downregulation of the sodium channel SCN5A. Relieving the inhibition of miR-448 facilitates the upregulation of SCN5A, which is protective against arrhythmia, while bypassing the potential pro-arhythmic side-effects of existing therapies.
Phase of Development
In vitro and in vivo testing.
This technology is now available for:
- Sponsored research